Previous studies have linked the use of testosterone replacement therapy with an increased risk of cardiovascular events such as heart attacks, stroke and death. A new study presented at the American Urological Association’s 2018 annual meeting raised new concerns. Researchers from Brigham and Women’s Hospital and Harvard Medical School in Boston found that men who used testosterone treatments are at an increased risk for urinary stones.
The study involved more than 26,000 men aged 40 to 64 who received continuous testosterone replacement therapy who were compared to similar men (based on age, race, marital status and other factors) who had never used the male hormone treatment. Researchers found a significantly higher incidence of urinary stones among men who were treated with testosterone treatments – 659 men in the testosterone group compared to 482 men in the control group.
A sub-analysis revealed that the greatest risk of urinary stone was with both topical gels and injections of testosterone. Testosterone pellets did not show the same risks.
Researchers launched the study after noting the prior animal studies have suggested that testosterone may increase the renal oxalate excretion and decrease citrate excretion, which may increase the risk of urinary stones.
Urinary stones, or kidney stones, are pieces of solid material that form in the kidneys when minerals in the urine become very concentrated. Small stones often pass through the body with little discomfort, but larger stones can be very painful and even block the urinary tract.
“Given this is the first study to specifically examine the relationship of testosterone replacement therapy with stone events, we feel that our findings can be considered alongside other known risks and benefits of TRT (testosterone replacement therapy) as clinicians counsel their patients and determine appropriate candidates for therapy,” Dr. Tyler R. McClintock told Renal & Urology News.
Source: Renal & Urology News